← Leaderboards
Ru Zhou
Oncotab, Inc
$530,294
Attributed
$1,060,588
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $660.6K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,060,588 · 3
By mechanism
R41$1,060,588 · 3
Top collaborators
- Pinku Mukherjee3 shared
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMalignant NeoplasmsSurvival RateTumor AntigensDesignMouse ModelMucin 1 ProteinSurfaceTargeted TreatmentAntibodiesMalignant Neoplasm Of PancreasDiagnosisCessation Of LifePancreatic Ductal AdenocarcinomaInterestImmunohistochemistryLabelGlycoproteinsExcisionImmuneDoseApicalEnsureDisease Progression
Grant awards (3)
Optimized targeted radiotherapy of pancreatic cancer$400,000
R41 · FY2025 · CA
An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.$400,000
R41 · FY2021 · CA
The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma$260,588
R41 · FY2021 · CA